Brand
XARELTO
XARELTO is an oral anticoagulant. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and says it was co-developed with Bayer HealthCare AG.
Documented stakes
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The filing says XARELTO was co-developed with Bayer HealthCare AG.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission